aTyr Pharma, Inc. (ATYR) NASDAQ
0.75
-0.0407(-5.13%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.75
-0.0407(-5.13%)
Currency In USD
| Previous Close | 0.79 |
| Open | 0.78 |
| Day High | 0.79 |
| Day Low | 0.75 |
| 52-Week High | 7.29 |
| 52-Week Low | 0.64 |
| Volume | 1.3M |
| Average Volume | 1.83M |
| Market Cap | 73.73M |
| PE | -0.94 |
| EPS | -0.8 |
| Moving Average 50 Days | 0.86 |
| Moving Average 200 Days | 2.42 |
| Change | -0.04 |
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
GlobeNewswire Inc.
Feb 03, 2026 1:00 PM GMT
Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nas
aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 10, 2025 1:00 PM GMT
SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announce
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
GlobeNewswire Inc.
Sep 30, 2025 9:30 AM GMT
Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0226). Improvement in King